{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-050164","form_type":"8-K","ticker":"AORT","cik":"0000784199","company_name":"ARTIVION, INC.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.154233+00:00","generated_at":"2026-05-17T00:05:52.486592+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Artivion Q3 rev $113.4M (+18% YoY), net income $6.5M; raises FY guidance","bullets":["Revenue $113.4M, up 18% GAAP/16% constant currency YoY; net income $6.5M ($0.13 EPS) vs loss of $2.3M.","Adjusted EBITDA $24.6M, up 39% from $17.7M; non-GAAP EPS $0.16 vs $0.12.","Stent grafts +38%, On-X +25%, preservation +5%, BioGlue +2% YoY.","Enrolled first patient in ARTIZEN IDE trial for Arcevo; refinanced credit to 2031 with $150M delayed draw.","Raises FY 2025 revenue guidance to $439-$445M (prev $435-$443M) and EBITDA to $88-$91M (prev $86-$91M)."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-050164","json":"https://secwatch.observer/filing/0001628280-25-050164.json","markdown":"https://secwatch.observer/filing/0001628280-25-050164.md","text":"https://secwatch.observer/filing/0001628280-25-050164.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/784199/000162828025050164/0001628280-25-050164-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/784199/000162828025050164/aort-20251106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:05:52.486592+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}